Appointment of Company Secretary and Compliance Officer
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
At a board meeting on May 30, 2025, Remedium Lifecare approved audited financial results for Q4 and FY ending March 31, 2025, along with several key governance appointments. Two new independent directors, Mr. Bikram Kumar Mund and Mr. Vijay Pal Singh Gulya, were each appointed for a 5-year term effective May 30, 2025. Mr. Kapil Goplani was appointed as Company Secretary cum Compliance Officer effective June 1, 2025, and Ms. Riddhi Shah was named Secretarial Auditor for a 5-year period (FY2025-26 to FY2029-30). On a consolidated basis, FY25 total income stood at ₹41,605.37 lakhs with profit after tax of ₹212.94 lakhs (EPS ₹0.05), though Q4 alone posted a loss of ₹204.60 lakhs. Total assets ballooned to ₹1,72,034.90 lakhs, largely due to the new Singapore-based subsidiary Remlife Global PTE which began operations in Q4 FY25. The statutory auditor issued an unmodified opinion, and qualified borrowings remained NIL.
The flurry of independent director and key managerial personnel additions suggests a governance upgrade rather than any shake-up, generally a positive signal for compliance posture. Investors should note the massive asset growth is driven by the new Singapore subsidiary, while profitability remains thin — the company posted a Q4 loss and a small full-year profit, so watch for margin trends going forward.